Rokaya El-Ansari
Overview
Explore the profile of Rokaya El-Ansari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel R, Alfarsi L, El-Ansari R, Masisi B, Erkan B, Fakroun A, et al.
Pathobiology
. 2024 Jun;
91(6):411-421.
PMID: 38861938
Introduction: ATF4, a stress-responsive transcription factor that upregulates adaptive genes, is a potential prognostic marker and modulator of glutamine metabolism in breast cancer. However, its exact role remains to be...
2.
Nath P, Alfarsi L, El-Ansari R, Masisi B, Erkan B, Fakroun A, et al.
Cancer Biol Ther
. 2023 Dec;
25(1):2291855.
PMID: 38073087
Breast cancer (BC), characterized by its diverse molecular profiles and clinical outcomes, presents a significant challenge in the development of effective therapeutic strategies. Metabolic reprogramming, a defining characteristic of cancer,...
3.
Morotti M, Zois C, El-Ansari R, Craze M, Rakha E, Fan S, et al.
Br J Cancer
. 2020 Oct;
124(2):494-505.
PMID: 33028955
Background: Glutamine (Gln) is an abundant nutrient used by cancer cells. Breast cancers cells and particularly triple-receptor negative breast cancer (TNBC) are reported to be dependent on Gln to produce...
4.
Alfarsi L, El-Ansari R, Craze M, Masisi B, Mohammed O, Ellis I, et al.
Int J Mol Sci
. 2020 Feb;
21(4).
PMID: 32093034
The majority of breast cancers are oestrogen-receptor-positive (ER+) and are subject to endocrine therapy; however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. The SLC7A5/SLC3A2 complex is...
5.
El-Ansari R, Craze M, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan C, et al.
Breast Cancer Res Treat
. 2019 Jan;
175(1):27-38.
PMID: 30671766
Purpose: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity, and patient outcome. Glutamine availability for growth and progression of BC is important in several BC...
6.
Craze M, El-Ansari R, Aleskandarany M, Cheng K, Alfarsi L, Masisi B, et al.
Breast Cancer Res Treat
. 2018 Nov;
174(1):79-91.
PMID: 30470977
Background: Dysregulated cellular metabolism is one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a...
7.
Luan H, Mohapatra B, Bielecki T, Mushtaq I, Mirza S, Jennings T, et al.
Cancer Res
. 2018 Mar;
78(10):2524-2535.
PMID: 29510992
CHIP/STUB1 ubiquitin ligase is a negative co-chaperone for HSP90/HSC70, and its expression is reduced or lost in several cancers, including breast cancer. Using an extensive and well-annotated breast cancer tissue...
8.
Craze M, Cheung H, Jewa N, Coimbra N, Soria D, El-Ansari R, et al.
Br J Cancer
. 2017 Nov;
118(2):258-265.
PMID: 29169183
Background: Altered cellular metabolism is a hallmark of cancer and some are reliant on glutamine for sustained proliferation and survival. We hypothesise that the glutamine-proline regulatory axis has a key...